Cranston Lynda Sarah 4
4 · DelMar Pharmaceuticals, Inc. · Filed Jun 30, 2020
Insider Transaction Report
Form 4
Cranston Lynda Sarah
Director
Transactions
- Other
Common Stock
2020-06-30−8→ 332 total(indirect: Held by J.G. Cranston & Associates, Inc.) - Award
Option (Right to Buy)
2020-06-26+39,567→ 75,000 totalExercise: $0.61Exp: 2029-09-05→ Common Stock (39,567 underlying)
Footnotes (3)
- [F1]The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
- [F2]On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
- [F3]The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.